CD3 X ROR2 DuoBodyTM therapy (Traverse Biotech/Genmab)

N/A

Report date: 2026/03/19 17:12:27

Base Information

Drug NameCD3 X ROR2 DuoBodyTM therapy (Traverse Biotech/Genmab)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Tyrosine-protein kinase transmembrane receptor ROR2 inhibitors

TargetsT cell surface glycoprotein CD3Tyrosine-protein kinase transmembrane receptor ROR2

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsLymphoma, Primary Cutaneous Anaplastic Large Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTraverse Biotech Inc Genmab A/S

China Registration ClassN/A

Develop Information

Active CompaniesTraverse Biotech Inc Genmab A/S

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungOvarian NeoplasmsLymphoma, Primary Cutaneous Anaplastic Large Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A